Beijing, Sept 1, 2026 — China’s Center for Medical Device Evaluation (CMDE) released 16 draft registration and review guidelines for Class II in vitro diagnostic (IVD) reagents and medical devices, opening a public comment period through Oct 8, 2026, as regulators standardize market entry requirements for diagnostic testing products including parathyroid hormone assay reagents.

Regulatory Snapshot

Key Scope

The batch covers registration and review technical standards for 16 categories of Class II IVD reagents and devices. The lead document addresses parathyroid hormone assay reagents, with the full portfolio spanning diverse diagnostic testing categories.

Market Impact Analysis

The simultaneous release of 16 draft guidelines represents a significant standardization effort for mid-risk diagnostic products, creating a comprehensive regulatory roadmap for IVD manufacturers navigating China’s Class II registration pathway. For domestic and international diagnostic makers, the consolidated guidance reduces interpretive ambiguity during application preparation, potentially shortening registration timelines by clarifying technical documentation, performance evaluation, and clinical evidence requirements.

The Oct 8 comment deadline provides a five-week window for industry feedback, suggesting regulators aim to finalize the guidelines by year-end. The focus on Class II IVD reagents—a category that includes immunoassay kits, clinical chemistry reagents, and molecular diagnostic products—signals intensified scrutiny of diagnostic devices that are widely used in clinical laboratories but produced by a fragmented supplier base.

Forward-Looking Statement

Industry analysts expect the finalized 16 guidelines to take effect in early 2027, establishing the definitive regulatory baseline for Class II IVD registrations through the remainder of the decade. Manufacturers with pending applications or pipeline products in the covered categories should review the drafts closely, as final versions may introduce new analytical performance requirements or clinical validation standards not explicitly mandated under previous informal guidance. The bulk release approach suggests CMDE is moving toward systematic catalog-wide standardization rather than reactive, product-specific rulemaking, a shift that could accelerate overall review efficiency but demands proactive compliance monitoring across broad diagnostic portfolios.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/flfg/zdyz/zqyjg/20260901133826130.html

Beijing, Sept 1, 2026 — China’s Center for Medical Device Evaluation (CMDE) released 59 draft registration and review guidelines for Class II active medical devices, opening a public comment period through Oct 8, 2026, as regulators standardize market entry requirements for powered equipment ranging from negative pressure suction devices to electronic diagnostic instruments.

Regulatory Snapshot

Key Scope

The batch covers registration and review technical standards for 59 categories of Class II active medical devices—equipment that relies on electrical energy or other power sources rather than human or gravitational force. The lead document addresses negative pressure source suction devices, with the full portfolio spanning diverse powered medical equipment categories.

Market Impact Analysis

The simultaneous release of 59 draft guidelines represents one of CMDE’s largest standardization efforts for mid-risk active devices, creating a comprehensive regulatory roadmap for manufacturers navigating China’s Class II registration pathway. For domestic and international device makers, the consolidated guidance reduces interpretive ambiguity during application preparation, potentially shortening registration timelines by clarifying technical documentation, clinical evidence, and testing requirements.

The Oct 8 comment deadline provides a five-week window for industry feedback, suggesting regulators aim to finalize the guidelines by year-end. The focus on Class II active devices—a category that includes infusion pumps, patient monitors, and therapeutic ultrasound equipment—signals intensified scrutiny of powered devices that pose moderate risk but are produced by a fragmented supplier base.

Forward-Looking Statement

Industry analysts expect the finalized 59 guidelines to take effect in early 2027, establishing the definitive regulatory baseline for Class II active device registrations through the remainder of the decade. Manufacturers with pending applications or pipeline products in the covered categories should review the drafts closely, as final versions may introduce new testing protocols or clinical data requirements not explicitly mandated under previous informal guidance. The bulk release approach suggests CMDE is moving toward systematic catalog-wide standardization rather than reactive, product-specific rulemaking, a shift that could accelerate overall review efficiency but demands proactive compliance monitoring across broad device portfolios.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/flfg/zdyz/zqyjg/20260901134127123.html